Immuneering Corp (IMRX) CFO discloses 225,000 Class A shares
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Immuneering Corp executive Andrew Gengos, Chief Financial Officer, reports ownership of 225,000 shares of Class A Common Stock, held directly. This disclosure outlines his reported equity stake as an officer and does not list any open-market transactions or derivative positions.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Gengos Andrew
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Class A Common Stock | -- | -- | -- |
Holdings After Transaction:
Class A Common Stock — 225,000 shares (Direct)
Footnotes (1)
Key Figures
Shares beneficially owned: 225,000 shares
Holding entries reported: 1
Reported buy transactions: 0
3 metrics
Shares beneficially owned
225,000 shares
Class A Common Stock held directly by CFO Andrew Gengos
Holding entries reported
1
Number of non-transactional holding rows in this ownership report
Reported buy transactions
0
Open-market purchase transactions included for Andrew Gengos
Key Terms
Class A Common Stock, transaction code, direct or indirect ownership
3 terms
Class A Common Stock financial
"security_title: Class A Common Stock reported for Andrew Gengos"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
transaction code regulatory
"transaction_code_description: Unknown transaction code"
direct or indirect ownership regulatory
"direct_or_indirect uses D/I for Direct/Indirect ownership type"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
Who is the insider reporting ownership in Immuneering Corp (IMRX)?
The insider is Andrew Gengos, who serves as Chief Financial Officer of Immuneering Corp. The report reflects his role as an officer and provides details on his equity holdings in the company’s Class A Common Stock.
Does this Immuneering (IMRX) Form 3 show any insider buying or selling by the CFO?
No, the report does not show any insider buying or selling by the CFO. It records a holding entry only, without any open-market purchase or sale transactions associated with the reported Class A Common Stock.
Does the Immuneering (IMRX) Form 3 disclose any derivative securities for Andrew Gengos?
No, the report lists no derivative securities for Andrew Gengos. The derivative section is empty, indicating there are no options, warrants, or other derivative positions reported alongside his Class A Common Stock holdings.